Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.535 +0.055 (+1.23%)
Streaming Delayed Price Updated: 10:19 AM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
The news is likely to come as a relief to many investors, Citi told investors in a research note. 
Via Stocktwits
Topics Intellectual Property
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines. 
Via Stocktwits
Topics Intellectual Property
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance ↗
 
Via Benzinga
News headline image
Recap: Arbutus Biopharma Q1 Earnings ↗
 
Via Benzinga
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based... 
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Arbutus Biopharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
Why Arbutus Biopharma Stock Is Sinking Today ↗
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump. 
Via The Motley Fool
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the... 
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the... 
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Why Arbutus Biopharma Stock Is Plunging Today ↗
 
Via Benzinga
Arbutus Biopharma's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Arbutus Biopharma (NASDAQ:ABUS) Shows Strong Technical and Fundamental Momentum ↗
Arbutus Biopharma (ABUS) shows strong technical health and high-growth momentum, with surging sales and earnings, positioning it for potential gains. 
Via Chartmill
News headline image
Arbutus (ABUS) Q2 Revenue Surges 529% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
News headline image
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts ↗
While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why. 
Via InvestorPlace
Topics Workforce
News headline image
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 ↗
ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble ↗
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood. 
Via InvestorPlace
News headline image
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge ↗
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology. 
Via Benzinga
Topics Intellectual Property
News headline image
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead ↗
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth. 
Via Benzinga
Topics Intellectual Property
News headline image
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim ↗
Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court. 
Via Benzinga
Topics Intellectual Property
News headline image
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute ↗
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma ↗
 
Via Benzinga
News headline image
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗
 
Via Benzinga
News headline image
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.